SRZN Surrozen, Inc./DE

$23.50 -1.67%

Healthcare · Biological Products, (No Diagnostic Substances)

Surrozen, Inc./DE (SRZN) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $273 million. Shares last traded at $23.50, 32.5% below their 52-week high. Over the past year the stock is up 138.1%. Net profit margin is -6960.8%, below the peer median of 6.3%. Revenue declined 67.4% year over year.

Market Cap

$273M

Shares Out

11.6M

EPS (TTM)

$-26.72

P/E Ratio

—

P/S Ratio

78.47

P/B Ratio

—

Dividend / Share

—

Dividend Yield

—

52-Week High

$34.82

52-Week Low

$8.07

Volume

4,290

Avg Vol (3m)

6,459.27

Performance

+0.56%

-7.92%

-11.19%

+6.29%

YTD

+8.34%

+138.10%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

43.71

SMA (50)

$27.87

SMA (200)

$21.29

Price vs SMA50

-15.69%

Price vs SMA200

+10.36%

ATR (14)

$2.31

Financials

Revenue

$3M

Net Income

$-242M

Gross Margin

—

Operating Margin

-1210.6%

Net Margin

-6960.8%

Return on Equity

87.0%

Return on Assets

-200.5%

Current Ratio

11.91

Debt / Equity

-1.43

Revenue Growth (YoY)

-67.4%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

Period	EPS (diluted)	Reported
Q1 2026	$-11.65	2026-05-06
FY 2025	$-32.37	2026-03-23
Q3 2025	$-8.49	2025-11-07
Q2 2025	$0.85	2025-08-08
Q1 2026	$-7.43	2026-05-06
FY 2025	$-21.67	2026-03-23

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

SRZN vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers

78.47 / 5.21 med

+1405% premium

Net margin vs peers

-6960.8% / 6.3% med

below median

1–14 of 14


AMGN	Amgen	$182.1B	23.62	4.96	21.0%	-1.27%
GILD	Gilead Sciences	$153.5B	18.04	5.21	28.9%	-1.46%
RVMD	Revolution Medicines, Inc.	$34.6B	-30.62	—	—	+3.14%
BIIB	Biogen	$29.0B	22.44	2.93	13.1%	-1.15%
MRNA	Moderna	$25.4B	-8.99	—	—	+3.22%
NBIX	Neurocrine Biosciences Inc	$15.9B	33.24	5.56	16.7%	-0.48%
EXEL	Exelixis, Inc.	$13.1B	16.68	5.62	33.7%	-1.04%
KRYS	Krystal Biotech, Inc.	$10.2B	50.02	26.33	52.6%	+1.68%
TECH	Bio-Techne	$9.1B	123.61	7.44	6.0%	+5.36%
HALO	Halozyme Therapeutics, Inc.	$8.1B	25.67	5.82	22.7%	-0.03%
IBRX	Immunitybio, Inc.	$7.7B	-21.87	—	—	+5.01%
RGEN	Repligen Corp	$7.4B	152.27	10.08	6.6%	-1.20%
KYMR	Kymera Therapeutics, Inc.	$7.4B	23.88	—	—	+0.44%
PCVX	Vaxcyte, Inc.	$7.4B	-9688.00	—	—	+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.